Name : Biotinylated Human LY6G6D Protein
Product Source :
Recombinant Biotinylated Human LY6G6D Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Asn20-Ser104.[Accession | O95868]
Molecular Weight :
The protein has a predicted MW of 12.79 kDa. Due to glycosylation, the protein migrates to 15-20 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Biotinylated Human LY6G6D on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. ELISA Data Immobilized Biotinylated Human LY6G6D, His-Avi Tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-LY6G6D Antibody, hFc Tag with the EC50 of 4.4ng/ml determined by ELISA.
Background :
LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.LY6G6D was identified as a selectively expressed CRC antigen that can be utilized to potently re-direct and activate cytotoxic T-cells to lyse LY6G6D expressing CRC using a TcE. This effect can be spread to target negative neighboring tumor cells, potentially leading to improved therapeutic efficacy.
Synonyms :
Protein Ly6-D; C6orf23; G6D; MEGT1; NG25
References & Citations :
Corrales L, Hipp S, Martin K, Sabarth N, Tirapu I, Fuchs K, Thaler B, Walterskirchen C, Bauer K, Fabits M, Bergmann M, Binder C, Chetta PM, Vogt AB, Adam PJ. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager. Front Immunol. 2022 Sep 8;13:1008764. doi: 10.3389/fimmu.2022.1008764. PMID: 36159851; PMCID: PMC9493073.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
HER2/CD340 Protein
IL-18 Protein
Popular categories:
Epithelial Cell Adhesion Molecule (EpCAM)
CD185/CXCR5